Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

British Journal of Surgery

Volumn 88, Issue 7, 2001, Pages 913-930

  Mismetti, P ^a   Laporte, S ^a,c   Darmon, J Y ^b   Buchmuller A ^a   Decousus, H ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b Medibridge Clinical Research   (France)

^c SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; DALTEPARIN; DIHYDROERGOTAMINE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; TINZAPARIN;

ARTICLE; BLEEDING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENERAL SURGERY; HEMATOMA; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0035668874     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1323.2001.01800.x     Document Type: Article

References (107)

1. Prevention of venous thromboembolism
2. Prevention of venous thromboembolism. International consensus statement
3. Are symptomatic endpoints acceptable in venous thromboprophylactic studies?
4. Low molecular weight heparin in prevention of perioperative thrombosis
5. Prophylaxis of postoperative thromboembolism with low molecular weight heparins
6. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials
7. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery
8. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: A systematic review of the randomized trials comparing anticoagulants with control
9. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
10. Efficacy and safety of Clivarin® and other LMWHs in general surgery: A meta-analysis
11. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses
12. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: A meta-analysis of randomised clinical trials
13. EasyMA: A program for the meta-analysis of clinical trials
14. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism
15. A multicenter study on LMW-heparin effectiveness in preventing post surgical thrombosis
16. Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose finding study
17. Low molecular weight heparin (Fluxum®) prevention of post-operative thrombosis in urological surgery. A controlled study
18. Prophylaxis of thromboembolism with low molecular weight heparin after surgical treatment. Preliminary notes
19. Low molecular weight heparin (parnaparin) versus calcium heparin in the prevention of thromboembolic disease in general surgery
20. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: Play-the-winner designed study
21. Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study
22. Prophylaxis of deep venous thrombosis with 2500 anti-Xa-E units of low molecular weight heparin Kabi in abdominal surgery
23. Dose-effect relationship in the prevention of post-surgical thromboembolism by a low molecular weight heparin. A multicenter study
24. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin
25. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients
26. Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism
27. Efficacy and safety of Fraxiparine® in the prevention of thromboembolic complications in oncologic thoracic surgery
28. Incidence and prevention of deep venous thrombosis occurring late after general surgery: Randomised controlled study of prolonged thromboprophylaxis
29. DVT prophylaxis in surgery for digestive tract cancer comparing the LMW heparinoid Org 10172 (Lomoparan) with calcium heparin
30. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison
31. A double blind placebo controlled study on the efficacy of low molecular weight heparin (LMWH) (K 2165) to prevent deep vein thrombosis in elective abdominal surgery
32. Prevention of thrombosis in surgery: Low molecular weight heparin/standard heparin
33. Subcutaneous enoxaparine (Lovenox®) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP)
34. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis
35. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin)
36. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin CY 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP)
37. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP)
38. Efficacy and safety of nadroparin (Fraxiparine®) versus placebo in the prophylactic treatment of deep vein thrombosis in patients with high thrombo-embolic risk undergoing general surgery
39. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216)
40. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial
41. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients
42. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis
43. A randomized study of a semisynthetic heparin analogue and heparin in prophylaxis of deep vein thrombosis
44. Efficacy and safety of low- molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study
45. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
46. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis
47. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis
48. Effectiveness and side effects of low-molecular weight heparin-dihydroergotamine in preventing thromboembolism in abdominal surgery
49. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7500 and 2500 anti-Xa IU/day)
50. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin
51. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
52. Descriptive analysis of the European Fraxiparin study
53. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
54. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
55. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: A comparison with low-dose heparin
56. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial
57. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery
58. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
59. Prevention of thromboembolic disease in general surgery with enoxaparin
60. Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane)
61. Prevention of thromboembolic disease in general surgery with Clexane® (enoxaparin)
62. Prevention of postoperative thromboembolism in general surgery with enoxaparin
63. Antithrombotic defense during the postoperative period. Clinical documentation of low molecular weight heparin
64. Prevention of thromboembolism in hysterectomies with low molecular weight heparin
65. Prevention of postoperative deep vein thrombosis by two different heparin types
66. A new low molecular weight heparin for deep vein thrombosis prevention: Effectiveness in postoperative patients
67. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis
68. Thromboembolism prophylaxis with low molecular heparin in abdominal surgery
69. Prevention of thrombosis in gynecology: Double-blind comparison of low molecular weight heparin and unfractionated heparin
70. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine
71. Prevention of post-operative deep vein thrombosis (DVT) in malignant patients by Fraxiparine (a low molecular weight heparin). A cooperative trial
72. Role of low molecular weight heparin in the prevention of postoperative deep venous thrombosis. Our experience in 88 cases
73. Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery
74. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin
75. Perioperative thromboembolic prophylaxis with low molecular weight heparin and postoperative bleeding complications
76. Prophylaxis of thromboembolism in elective abdominal surgery. Comparison of efficacy and safety of low molecular weight heparin and unfractionated heparin
77. Comparison of low molecular weight heparin CY 216 and unfractionated heparin in preventing post-operative venous thromboembolism in general surgery: A preliminary results of a cooperative study
78. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin
79. Prophylaxis of thromboembolism in abdominal surgery. Effectiveness and tolerance of low molecular weight heparin in combination with dihydroergotamine
80. Comparison of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy
81. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery
82. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin
83. Perioperative prevention of thromboembolism with standard heparin and low molecular weight heparin, evaluation of postoperative hemorrhage. A double-blind prospective, randomized and mono-center study
84. Post-surgical deep vein thrombosis prevention: Evaluation of the risk/benefit ratio of fractionated and unfractionated heparin
85. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
86. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group
87. Patients at risk of venous thromboembolism - Clinical results with reviparin
88. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
89. Comparison of the efficacy and safety of subcutaneous RD heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic surgery for cancer
90. Enoxaparin in the prevention of deep venous thrombosis after major surgery: Multicentric study
91. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis
92. Efficiency and tolerance of Fraxiparine® in the prevention of deep vein thrombosis in general surgery performed with medullar conduction anesthesia
93. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery
94. Thromboprophylaxis in colorectal surgery. A randomized trial comparing low dose heparin and enoxaparin
95. Thromboprophylaxis in colorectal surgery. A randomized trial comparing low dose heparin to enoxaparin
96. Thromboprophylaxis after colorectal surgery. Results of a randomized, double-blind comparison of low dose heparin and enoxaparin
97. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery
98. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
99. Prevention of postoperative venous thrombosis. A randomized trial comparing low-dose heparin and low molecular weight heparin in gynaecological oncology
100. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: Efficacy, safety, and follow-up
101. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin. A double blind comparison of certoparin and unfractionated heparin
102. Risk and prophylaxis for venous thromboembolism in hospital patients
103. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials
104. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
105. Antithrombotic therapy for venous thromboembolic disease